Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) agreed to acquire Exclusive Worldwide License for Actinium-Based PSMA Targeted Radiotherapy from Heidelberg University and Euratom represented by the European Commission, Joint Research Centre on February 16, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.55 USD | +0.14% |
|
0.00% | +124.25% |
Jun. 04 | Fusion Pharmaceuticals Says $2.4 Billion Acquisition by AstraZeneca Unit Is Complete | MT |
Jun. 04 | Fusion Pharmaceuticals Inc.(NasdaqGS:FUSN) dropped from NASDAQ Biotechnology Index | CI |
- Stock Market
- Equities
- FUSN Stock
- News FUSN PHAR
- Fusion Pharmaceuticals Inc. agreed to acquire Exclusive Worldwide License for Actinium-Based PSMA Targeted Radiotherapy from Heidelberg University and Euratom represented by the European Commission, Joint Research Centre.